From October 24-26, the CPHI Worldwide 2023 was held at the Fira Barcelona Gran Via in Barcelona, Spain. Henlius, along with its wholly-owned subsidiary, Aton Biotech, a biologics CDMO, made a significant presence and showcased a wide range of innovative research and development accomplishments and its integrated biopharmaceutical platform.
CPHI Worldwide is the world's largest gathering in the pharmaceutical industry, attracting leading pharmaceutical companies and investors from around the world. This year, it successfully brought together over 65,000 industry professionals and near 2,000 exhibitors. Henlius attracted traffic at the booth, and concluded the conference with over 60 meetings for potential collaboration.
Cao Ping, Senior Vice President and Chief Business Development Officer at Henlius, highlighted the importance of CPHI Worldwide. "CPHI Worldwide offers a valuable platform to explore cutting-edge industry technologies and collaborative opportunities. We have the opportunity to communicate, share good practices, and exchange experiences with the professionals from around the world and seek more possibilities for partnership to jointly provide high-quality, affordable biologics to patients worldwide."
During CPHI Barcelona 2023, Henlius showcased 5 launched products at Booth #1D50, including HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab for injection, trade name in Europe: Zercepac®; trade names in Australia: Tuzucip® and Trastucip®, the first China-developed mAb biosimilar approved both in China and Europe, HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), and its innovative product HANSIZHUANG, the world’s first anti-PD-1 monoclonal antibody (mAb) for the first-line treatment of SCLC. These products have gained recognition from various global partners, including Abbott, Accord Healthcare, Getz Pharma, Eurofarma, and KGbio. Additionally, the company prides itself on HANQUYOU has obtained marketing approvals in over 40 countries, including the United Kingdom (UK), France, Germany, Switzerland, Australia, Singapore, Argentina, and Saudi Arabia. In addition, the Biologics License Application (BLA) for HANQUYOU has been accepted by the FDA, which will further expand the product's footprint in major markets of biologics in the U.S. and Europe. Apart from the launched products, Henlius has pro-actively built a diversified and high-quality product pipeline, including over 60 molecules across mAb, bispecific antibody (BsAb), ADC, fusion protein, and small molecule drug conjugate.
Not only does Henlius continue to invest in innovations, but the company also strictly follows the International Good Manufacturing Practice (GMP) standards for production and quality control. It has a total commercial manufacturing capacity of 48,000 litres. The company's commercial production facility and supporting quality management system have been certificated by China and the EU GMP. Recently, Henlius’ facility successfully passed GMP inspections conducted by overseas authorities, including the Indonesia’s National Agency for Drug and Food Control (BPOM) and Brazilian National Health Surveillance Agency (ANVISA), a participating member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These achievements will strongly support the continued growth of market share worldwide.
Looking ahead, Henlius will maintain its focus on unmet medical and market needs; develop more high-quality, affordable, and innovative biologics; advance its global R&D, production, and commercialization capabilities; expand international collaborations, and accelerate building a global presence to benefit patients worldwide.